InterCure Ltd. (
NASDAQ:INCR -
Get Free Report)'s share price traded up 2.1% on Thursday . The stock traded as high as $1.50 and last traded at $1.49. 34,365 shares traded hands during mid-day trading, a decline of 3% from the average session volume of 35,331 shares. The stock had previously closed at $1.46.
InterCure Price Performance
The stock has a fifty day moving average of $1.51 and a two-hundred day moving average of $1.53. The company has a quick ratio of 1.18, a current ratio of 1.73 and a debt-to-equity ratio of 0.34.
Institutional Investors Weigh In On InterCure
A hedge fund recently bought a new stake in InterCure stock. Moore Capital Management LP bought a new stake in InterCure Ltd. (NASDAQ:INCR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 97,273 shares of the company's stock, valued at approximately $156,000. Moore Capital Management LP owned about 0.21% of InterCure at the end of the most recent reporting period. 8.34% of the stock is currently owned by hedge funds and other institutional investors.
About InterCure
(
Get Free Report)
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider InterCure, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InterCure wasn't on the list.
While InterCure currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
